BCA
CRBP icon

Berman Capital Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Berman Capital Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10
Closed – – 2085
2021
Q2 		$0 Buy
+10
New +$555 ﹤0.01% 1917

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Berman Capital Advisors's CRBP Position: Q3 2021 in Review

Berman Capital Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2021, closing a stake of 10 shares.

Berman Capital Advisors first reported a position in CRBP in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 85 funds tracked by Wall St. Rank hold CRBP as of Q3 2021.

  • Berman Capital Advisors reported no remaining Corbus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 10 Corbus Pharmaceuticals shares in Q3 2021.
  • Berman Capital Advisors first reported a position in Corbus Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Berman Capital Advisors's Corbus Pharmaceuticals position peaked at $0 in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.